^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Esophageal Squamous Cell Carcinoma
    Drug:AiRuiKa (camrelizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC

    Excerpt:
    ...It can provide tumor tissue for the detection of PD-L1 expression level; 5....
    Trial ID:
    NCT05182944
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO Asia 2020
    Title:

    A prospective phase II clinical trial exploring neoadjuvant immunotherapy combined with chemotherapy in resectable thoracic esophageal squamous cell cancer (TESCC) with multi-station lymph node metastases (NICE study): Preliminary results

    Published date:
    11/17/2020
    Excerpt:
    This was an investigator-initiated trial for pts with newly diagnosed AJCC 8th resectable TESCC...Pts received 2 courses of camrelizumab...added to carboplatin...plus albumin paclitaxel...Pts with either PD-L1+ or PD-L1- had pCRs.
    Secondary therapy:
    carboplatin + albumin-bound paclitaxel